title: [Steatohepatitis after chemotherapy for colorectal liver metastases (CASH)].
abstract: Neoadjuvant chemotherapy provides an important treatment option for patients who, as a consequence of colorectal cancer, have developed liver metastases. Regression of metastases prior to surgery may substantially improve prognosis. However, chemotherapeutics may harm non-tumorous liver tissue, particularly if this is already impaired prior to chemotherapy. The present article discusses the risks of chemotherapeutics for liver tissue-including sinusoidal obstruction syndrome, nodular regenerative hyperplasia, and chemotherapy-associated steatohepatitis, amongst others-which should be borne in mind when selecting therapy.
authors.affiliation: Institut für Pathologie, Ruhr-Universität Bochum, 44789, Bochum, Deutschland. andrea.tannapfel@rub.de
authors.forename: A
authors.initials: A
authors.lastname: Tannapfel
authors.forename: A
authors.initials: A
authors.lastname: Reinacher-Schick
authors.forename: B
authors.initials: B
authors.lastname: Flott-Rahmel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D005234:Fatty Liver / Q000139:chemically induced*; D020518:Focal Nodular Hyperplasia / Q000139:chemically induced / Q000473:pathology; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D008854:Microscopy, Electron; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging
chemical_list: D000970:Antineoplastic Agents